ResearchMoz

Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018

Transparency Market Research
Published Date » 2013-03-13
No. Of Pages » 128
 
   
 Peptide therapeutics is currently offering a new commercial potential to pharmaceuticals and biotechnology industry. To exploit this emerging market, large pharmaceutical and biotechnological firms are actively investing in development of newer peptides for various applications and are also opting for newer technologies for syntheses of these peptides. Cancer is the leading cause of death globally; according to the WHO (World Health Organization), around 12.7 million new cancer cases occurred in the year 2008. About 7 million people die from cancer every year and it is estimated that there will be more than 16 million new cancer cases every year by 2020. With rise in cancer patients and metabolic diseases like diabetes, there has been a push in growth for peptide molecules...
Table of content

Chapter 1 Introduction
1.1 Report description
1.2 Market segmentation
1.3 Scope of the report
1.4 Research methodology
1.5 Assumptions

Chapter 2 Executive Summary
2.1.1 Global peptide therapeutics market revenues, 2010 – 2018 (USD Million)
2.1.2 Global peptide therapeutics market revenues, by region, 2010 - 2018 (USD Million)
2.1.3 Global API peptide therapeutics market, 2011 (USD Million)
2.1.4 Global peptide therapeutics market, by route of administration, 2011 & 2018 (%)

Chapter 3 Global Peptide Therapeutics Market Dynamics
3.1 Overview
3.2 Drivers
3.2.1 Increase in cancer patient population to propel the growth of new peptides
3.2.2 Rise in metabolic disorders to escalate the growth of peptides market
3.2.3 Rise in R&D pipeline of peptide drugs is expected to bring considerable growth in coming years
3.2.3.1 Global peptide therapeutics trials growth, 1970 - 2011
3.2.4 Technological enhancement has boosted the growth of the market with radical reduction in total production cost of peptides
3.3 Restraints & challenges
3.3.1 Increasing complexity of peptides is a huge challenge for manufacturers
3.3.2 Lack of regulatory standards hampering the growth of the market
3.3.3 Matching equipments with customer requirements is a major challenge for API peptide manufacturers
3.4 Opportunities
3.4.1 Rise in cancer vaccine to drive the future market
3.4.2 Generic peptides market to flourish with patent cliff expected in the forecast period
3.4.3 Small biotech firms collaborating with large pharmaceutical companies to explore further growth
3.4.3.1 Global scenario of acquisitions of biotech firms by large pharma giants
3.4.3.2 Major peptide drugs and sales, 2011 (USD Million)
3.5 Porters five forces analysis
3.5.1 Porter’s five forces analysis of global peptide therapeutics market
3.5.2 Bargaining power of suppliers
3.5.3 Bargaining power of buyers
3.5.4 Threat of new entrants
3.5.5 Threat of substitutes
3.5.6 Competitive rivalry
3.6 Market attractiveness analysis
3.6.1 Market attractiveness analysis of the peptide therapeutics market by geography
3.7 Peptide therapeutics - emerging technologies & trends
3.8 Regulatory policies

Chapter 4 Global Peptide Therapeutics Market Analysis, By Applications
4.1.1 Introduction
4.1.1.1 Global peptide therapeutics market revenue, by applications 2012-2018 (USD Million)
4.1.2 Cancer
4.1.2.1 Global cancer peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012
4.1.2.2 Global cancer peptide therapeutics market revenues, 2010 – 2018 (USD Million)
4.1.3 Metabolic
4.1.3.1 Global metabolic peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012
4.1.3.2 Global metabolic peptide therapeutics market revenues, 2010 – 2018 (USD Million)
4.1.4 Cardiovascular
4.1.4.1 Global cardiovascular peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012
4.1.4.2 Global cardiovascular peptide therapeutics market revenues, 2010 – 2018 (USD Million)
4.1.5 Dermatology
4.1.5.1 Global dermatology pipeline drugs analysis, number of trials, 2009 - 2012
4.1.5.2 Global dermatology peptides market revenues, 2010 – 2018 (USD Million)
4.1.6 Anti-Infection
4.1.6.1 Global anti-infection drugs analysis, number of trials, 2009 - 2012
4.1.6.2 Global anti-infection peptides market revenues, 2010 – 2018 (USD Million)
4.1.7 Neurology
4.1.7.1 Global neurology pipeline drugs analysis, number of trials, 2009 - 2012
4.1.7.2 Global neurology peptides market revenues, 2010 – 2018 (USD Million)
4.1.8 Gastro Intestinal
4.1.8.1 Global gastro intestinal pipeline drugs analysis, number of trials, 2009 - 2012
4.1.8.2 Global gastro intestinal peptides market revenues, 2010 - 2018 (USD Million)
4.1.9 Renal
4.1.9.1 Global renal pipeline drugs analysis, number of trials, 2009 - 2012
4.1.9.2 Global renal peptides market revenues, 2010 – 2018 (USD Million)
4.1.10 Respiratory
4.1.10.1 Global respiratory pipeline drugs analysis, number of trials, 2009 - 2012
4.1.10.2 Global respiratory peptides market revenues, 2010 – 2018 (USD Million)
4.1.11 Pain
4.1.11.1 Global pain pipeline drugs analysis, number of trials, 2009 - 2012
4.1.11.2 Global pain peptides market revenues, 2010 - 2018 (USD Million)
4.1.12 Others
4.1.12.1 Global other pipeline drugs analysis, number of trials, 2009 - 2012
4.1.12.2 Global other peptides market revenues, 2010 – 2018 (USD Million)

Chapter 5 Global Peptide Therapeutics Market, by Route of Administration
5.1 Introduction
5.1.1 Global peptide therapeutics market revenues, by route of administration, 2010 - 2018 (USD Million)
5.1.2 Methods of delivery for peptide drugs
5.2 Parenteral Route
5.2.1 Global peptide therapeutics market revenues, by parenteral route of administration, 2010 - 2018 (USD Million)
5.3 Oral Route
5.3.1 Global peptide therapeutics market revenues, by oral route of administration, 2010 - 2018 (USD Million)
5.4 Pulmonary Route
5.4.1 Global peptide therapeutics market revenues, by pulmonary route of administration, 2010 - 2018 (USD Million)
5.5 Mucosal Route
5.5.1 Global peptide therapeutics market revenues, by mucosal route of administration, 2010 - 2018 (USD Million)
5.6 Others (Intradermal & Nasal)
5.6.1 Global peptide therapeutics market revenues, by other routes of administration, 2010 - 2018 (USD Million)

Chapter 6 Peptide Therapeutics Market – Generic & Innovative Segments
6.1 Introduction
6.1.1 Global peptide therapeutics market, by types revenues, 2010 - 2018 (USD million)
6.2 Peptide Therapeutics – Innovative market
6.2.1 Global innovative peptide therapeutics market revenues, 2010 - 2018 (USD Million)
6.3 Peptide Therapeutics – Generic market
6.3.1 Global generic peptide therapeutics market revenues, 2010 - 2018 (USD Million)

Chapter 7 API Peptide Therapeutics Market, In-house Vs CMO
7.1 Introduction
7.2 API peptide therapeutics – In-house market
7.2.1 Global API peptide therapeutics in-house market revenues, 2010-2018 (USD Million)
7.3 Contract Manufacturing Organizations (CMO)
7.3.1 Global API peptide therapeutics CMOs market revenues, 2010 - 2018 (USD Million)

Chapter 8 Peptide Therapeutics Market, By Technology
8.1 Introduction
8.1.1 Global peptide therapeutics market revenues, by technology, 2010 – 2018 (USD Million)
8.2 Solid Phase Peptide Synthesis (SPPS)
8.2.1 Global peptide therapeutics SPPS technology market revenues, 2010 - 2018 (USD Million)
8.3 Liquid Phase Peptide Synthesis (LPPS)
8.3.1 Global peptide therapeutics LPPS technology market revenues, 2010 - 2018 (USD Million)
8.4 Hybrid Technology
8.4.1 Global peptide therapeutics hybrid technology market revenues, 2010 - 2018 (USD Million)

Chapter 9 Peptide Therapeutics Market, By Geography
9.1 Introduction
9.1.1 Global peptide therapeutics market share, by geography, 2011 - 2018
9.2 North America
9.2.1 North America peptide therapeutics market revenues, 2010 – 2018 (USD Million)
9.3 Europe
9.3.1 Europe peptide therapeutics market revenues, 2010 – 2018 (USD Million)
9.4 Asia 
9.4.1 Asia peptide therapeutics market revenues, 2010 - 2018 (USD Million)
9.5 Rest of World
9.5.1 RoW peptide therapeutics market revenues, 2010 - 2018 (USD Million)

Chapter 10 Market Share Analysis
10.1 Market share by key players
10.2 Market share by key players in peptide drugs market
10.2.1 Global peptide therapeutics market share analysis of key players, 2011 (%)
10.3 Market share by key players in CMO segment
10.3.1 Global peptide therapeutics: market share analysis of key CMO players, 2011 (%)

Chapter 11 Recommendations
11.1 Success strategies
11.1.1 Rigorous research and development (R&D) initiatives
11.1.2 Investing in emerging economies
11.1.3 Investing in recent technologies such as HPPS TEchnology
11.1.4 Mergers and acquisitions
11.2 Barriers to be considered
11.2.1 The high cost of peptide synthesis
11.2.2 Weak pipeline peptide drug candidates in phase III

Chapter 12 Company Profiles
12.1 Bachem Holding AG
12.1.1 Company overview
12.1.2 Financial overview
12.1.3 Strategic overview
12.1.3.1 Collaborations
12.1.3.2 Expansion
12.1.3.3 Divestiture
12.1.3.4 Recent developments
12.2 Eli Lilly and Company
12.2.1 Company overview
12.2.2 Financial overview
12.2.3 Strategic overview
12.2.3.1 Agreements
12.2.3.2 Approvals
12.2.4 Recent developments
12.3 Pfizer, Inc.
12.3.1 Company overview
12.3.2 Financial overview
12.3.3 Strategic overview
12.3.3.1 Mergers and acquisitions
12.3.3.2 Divestiture
12.3.3.3 Approvals
12.3.4 Recent developments
12.4 Amgen, Inc.
12.4.1 Company overview
12.4.2 Financial overview
12.4.3 Strategic overview
12.4.3.1 Mergers and acquisitions
12.4.3.2 Licensing
12.4.4 Recent developments
12.5 Takeda Pharmaceutical Company Limited
12.5.1 Company overview
12.5.2 Financial overview
12.5.3 Strategic overview
12.5.3.1 Partnerships and collaborations
12.5.3.2 Mergers and acquisitions
12.5.4 Recent developments
12.6 Teva Pharmaceuticals
12.6.1 Company overview
12.6.2 Financial overview
12.6.3 Strategic overview
12.6.3.1 Mergers and acquisitions
12.6.3.2 Investing in generic and biosimilar segments
12.6.4 Recent developments
12.7 Lonza Inc.
12.7.1 Company overview
12.7.2 Financial overview
12.7.3 Strategic overview
12.7.3.1 Investing in emerging economies
12.7.3.2 Mergers and acquisitions
12.7.4 Recent developments
12.8 Peptisyntha
12.8.1 Company overview
12.8.2 Financial overview
12.8.3 Strategic overview
12.8.3.1 Arranging and participating in trade shows
12.8.3.2 Continuous manufacturing expansion
12.9 Sanofi
12.9.1 Company overview
12.9.2 Financial overview
12.9.3 Strategic overview
12.9.3.1 Acquisitions
12.9.3.2 Divestments
12.9.4 Recent developments
12.10 Ipsen
12.10.1 Company overview
12.10.2 Financial overview
12.10.3 Strategic overview
12.10.3.1 Large investment in research and development
12.10.3.2 Global expansion through partnership
12.10.4 Recent developments
12.11 PolyPeptide Group.
12.11.1 Company overview
12.11.2 Strategic overview
12.11.2.1 Focus on product portfolio extension and quality product development
12.11.2.2 Global expansion through merger and acquisition
12.12 Amylin Pharmaceuticals LLC - Bristol-Myers Squibb (BMS)
12.12.1 Company overview
12.12.2 Amylin Pharmaceuticals LLC
12.12.3 Financial overview
12.12.4 Strategic overview (Amylin Pharmaceuticals LLC)
12.12.4.1 Entering into strategic collaborations
12.12.4.2 Corporate social responsibility
12.12.4.3 Rigorous R&D initiatives
12.12.5 Recent developments
12.13 AstraZeneca PLC
12.13.1 Company overview
12.13.2 Financial overview
12.13.3 Strategic overview
12.13.3.1 Rigorous R&D initiatives
12.13.3.2 Investing in emerging economies
12.13.4 Recent developments
12.14 Roche
12.14.1 Company overview
12.14.2 Financial overview
12.14.3 Strategic overview
12.14.3.1 Research and development initiatives
12.14.3.2 Focus on personalized healthcare
12.14.3.3 Focus on new and emerging markets
12.14.3.4 Funding awareness programs
12.14.4 Recent developments
12.15 GlaxoSmithKline (GSK)
12.15.1 Company overview
12.15.2 Financial overview
12.15.3 Strategic overview
12.15.3.1 Research and development initiatives
12.15.3.2 Direct to Consumer Advertising
12.15.3.3 Mergers and acquisitions
12.15.4 Recent developments
12.16 Merck & Co.
12.16.1 Company overview
12.16.2 Financial overview
12.16.3 Strategic overview
12.16.3.1 Corporate social responsibility
12.16.3.2 R&D Initiatives
12.16.3.3 Strategic alliances and out-licensing
12.16.4 Recent developments
12.17 Novartis AG
12.17.1 Company overview
12.17.2 Financial overview
12.17.3 Strategic overview
12.17.3.1 Mergers and acquisitions
12.17.3.2 Memorandum of understanding
12.17.4 Recent developments
12.18 Novo-Nordisk A/S
12.18.1 Company overview
12.18.2 Financial overview
12.18.3 Strategic overview
12.18.3.1 Partnerships and alliances
12.18.4 Agreements
12.18.5 Recent developments

List of Tables


TABLE 1 Global therapeutic peptides market: Snapshot 22
TABLE 2 Global peptide therapeutics market revenues, by region, 2010 - 2018 (USD Million) 23
TABLE 3 Global scenario of acquisitions of biotech firms by large pharma giants 31
TABLE 4 Major peptide drugs and sales, 2011 (USD Million) 31
TABLE 5 Global peptide therapeutics market revenue, by applications 2012-2018 (USD Million) 36
TABLE 6 Global peptide therapeutics market revenues, by route of administration, 2010 - 2018 (USD Million) 56
TABLE 7 Methods of delivery for peptide drugs 57
TABLE 8 Global peptide therapeutics market, revenues, by types 2010 - 2018 (USD million) 63
TABLE 9 Global API peptide therapeutics Market, By Revenue, by Types, 2010 - 2018 (USD million) 67
TABLE 10 Global peptide therapeutics market revenues, by technology, 2010 - 2018 (USD Million) 70
TABLE 11 Global Peptide Therapeutics Market, By Geography, 2010-2018 (USD Million) 75

List of Figures


FIG. 1 Global Peptide Therapeutics: Market Snapshot 18
FIG. 2 Global peptide therapeutics market, by revenue, 2010 – 2018 (USD Million) 23
FIG. 3 Global API peptide therapeutics market, 2011 (USD Million) 24
FIG. 4 Global peptide therapeutics market, by route of administration, 2011 & 2018 (%) 25
FIG. 5 Global peptide therapeutics trials growth, 1970 - 2011 27
FIG. 6 Porter’s five forces analysis for global peptide therapeutics market 32
FIG. 7 Market attractiveness analysis of the global peptide therapeutics market, by geography 34
FIG. 8 Global Cancer peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012 38
FIG. 9 Global cancer peptide therapeutics market revenues, 2010 - 2018 (USD Million) 39
FIG. 10 Global metabolic peptide therapeutics pipeline drugs analysis , number of trials, 2009 - 2012 40
FIG. 11 Global metabolic peptide therapeutics market revenues, 2010 - 2018 (USD Million) 40
FIG. 12 Global cardiovascular peptide therapeutics pipeline drugs analysis, number of trials, 2009 - 2012 41
FIG. 13 Global cardiovascular peptide therapeutics market revenues, 2010 - 2018 (USD Million) 42
FIG. 14 Global dermatology pipeline drugs analysis, number of trials, 2009 - 2012 43
FIG. 15 Global dermatology peptides market revenues, 2010 - 2018 (USD Million) 44
FIG. 16 Global anti-infection pipeline drugs analysis, number of trials, 2009 - 2012 45
FIG. 17 Global anti-infection peptides market revenues, 2010 - 2018 (USD Million) 46
FIG. 18 Global neurology pipeline drugs analysis, number of trials, 2009 - 2012 47
FIG. 19 Global neurology peptides market revenues, 2010 - 2018 (USD Million) 47
FIG. 20 Global gastro intestinal pipeline drugs analysis, number of trials, 2009 - 2012 48
FIG. 21 Global gastro intestinal peptides market revenues, 2010 - 2018 (USD Million) 49
FIG. 22 Global renal pipeline drugs analysis, number of trials, 2009 - 2012 50
FIG. 23 Global renal peptides market revenues, 2010 - 2018 (USD Million) 50
FIG. 24 Global respiratory pipeline drugs analysis, number of trials, 2009 - 2012 51
FIG. 25 Global respiratory peptides market, revenues, 2010 - 2018 (USD Million) 52
FIG. 26 Global pain pipeline drugs analysis, number of trials, 2009 - 2012 53
FIG. 27 Global pain peptides market revenues, 2010 - 2018 (USD Million) 53
FIG. 28 Global others pipeline drugs analysis, number of trials, 2009 - 2012 54
FIG. 29 Global others peptides market revenues, 2010 - 2018 (USD Million) 55
FIG. 30 Global peptide therapeutics market revenues, by parenteral route of administration, 2010 - 2018 (USD Million) 58
FIG. 31 Global peptide therapeutics market revenues, by oral route of administration, 2010 - 2018 (USD Million) 59
FIG. 32 Global peptide therapeutics market revenues, by pulmonary route of administration, 2010 - 2018 (USD Million) 60
FIG. 33 Global peptide therapeutics market revenues, by mucosal route of administration, 2010 - 2018 (USD Million) 61
FIG. 34 Global peptide therapeutics market revenues, by other routes of administration, 2010 - 2018 (USD Million) 62
FIG. 35 Global innovative peptide therapeutics market revenues, 2010 - 2018 (USD Million) 65
FIG. 36 Global generic peptide therapeutics market revenues, 2010 - 2018 (USD Million) 66
FIG. 37 Global API peptide therapeutics in-house market revenues, 2010 - 2018 (USD Million) 68
FIG. 38 Global API peptide therapeutics CMOs market revenues, 2010 - 2018 (USD Million) 69
FIG. 39 Global peptide therapeutics SPPS technology market revenues, 2010 - 2018 (USD Million) 71
FIG. 40 Global peptide therapeutics LPPS technology market revenues, 2010 - 2018 (USD Million) 72
FIG. 41 Global peptide therapeutics hybrid technology market revenues, 2010 - 2018 (USD Million) 73
FIG. 42 Global peptide therapeutics market, by geography, 2011 - 2018 74
FIG. 43 North America peptide therapeutics market revenues, 2010 - 2018 (USD Million) 76
FIG. 44 Europe peptide therapeutics market revenues, 2010 - 2018 (USD Million) 77
FIG. 45 Asia peptide therapeutics market revenues, 2010 - 2018 (USD Million) 78
FIG. 46 RoW peptide therapeutics market revenues, 2010 - 2018 (USD Million) 79
FIG. 47 Global peptide therapeutics market share analysis of key players, 2011 (%) 81
FIG. 48 Global peptide therapeutics: market share analysis of key CMO players, 2011 (%) 82
FIG. 49 Bachem Holding AG: annual revenues, 2009 – 2011 (USD Million) (conversion rate: 1 CHF = 1.06 USD) 87
FIG. 50 Eli Lilly & Company: annual revenues, 2009 – 2011 (USD Million) 89
FIG. 51 Pfizer, Inc.: annual revenues, 2009 – 2011 (USD Million) 91
FIG. 52 Amgen, Inc.: annual revenues, 2009 – 2011 (USD Million) 94
FIG. 53 Takeda Pharmaceutical Company Ltd.: annual revenues, 2009 – 2011 (USD Million) (conversion rate: 1 JPY = 0.01 USD) 97
FIG. 54 Teva Pharmaceuticals: annual revenues, 2009 – 2011 (USD Million) 99
FIG. 55 Lonza Inc.: annual revenues, 2009 – 2011 (USD Million) (conversion rate: 1 CHF = 1.06 USD) 101
FIG. 56 Solvay Group: annual revenues, 2010 – 2011 (USD Million) (conversion rate: 1 Euro = 1.34 USD) 103
FIG. 57 Sanofi: annual revenues, 2009 – 2011 (USD Million) 105
FIG. 58 Ipsen: annual revenue Share, by geography, 2010 & 2011 (%) 107
FIG. 59 Ipsen: annual revenues, 2009 - 2011 (USD Million) 108
FIG. 60 Bristol-Myers Squibb: annual revenues, 2009 – 2011 (USD Million) 112
FIG. 61 AstraZaneca PLC: annual revenues, 2009 – 2011 (USD Million) 114
FIG. 62 Roche: annual revenues, 2009 – 2011 (USD Million) (conversion rate: 1 CHF = 1.06 USD) 116
FIG. 63 GSK: annual revenues, 2009 – 2011 (USD million) (conversion rate: 1 GBP = 1.5849 USD) 118
FIG. 64 Merck & Co.: annual revenues, 2009 – 2011 (USD Million) 120
FIG. 65 Novartis AG: annual revenues, 2009 – 2011 (USD Million) 123

Upcoming Reports:

Greece: market of electric ceiling or wall lightning fittings
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the electric ceiling or wall lightning fittings market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the electric ceiling or wall lightning fittings market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In...
Greece: market of seats with metal frames
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the seats with metal frames market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the seats with metal frames market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an...
Coal Mining Market - Global Industry Analysis, Size, Share, Trends, Growth And Forecast, 2013 - 2019
By - Transparency Market Research
Coal is a global resource, its demand and price fluctuates frequently. In upcoming years the demand of coking coal will increase because of the requirement of developing countries for production of steel. The aim of coal mining is to extract coal from the ground. Mining of different types of coal takes place either underground or in surface pits. Most of the coal mines consist of bituminous, anthracite or lignite type of coal.  The developing countries have more demand for metallurgical coal for steel production. Further, the demand of electricity is expected to expand which...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

High-sodium Diet Increases Risks of Cardiovascular Diseases in Type 2 Diabetics
Jul 24, 2014  
A new research has found relation between the amount of salt in diet of diabetics and their chances of suffering from cardiovascular diseases. The research has stated that diabetics who have a high-salt diet are on a higher risk of having a chronic heart disease as compared to the ones who eat less salt.  The study’s findings provide evidences that support the benefits of a...
Strides Arcolab Bags USFDA Approval for Transplant Drug
Jul 24, 2014  
Indian pharmaceutical company Strides Arcolab has received the approval of the USFDA to sell its transplant drug Tacrolimus in the US market. The capsule is an immune-suppressant that is used for preventing organ rejection that may occur in transplant surgeries of organs such as kidneys, heart or liver in some patients.  USFDA has allowed the sale of the tablets in 5 mg, 1 mg and 0.5...
Chinese manufacturing gauge gets a hike after months
Jul 24, 2014  
China manufacturing gauge has climbed to its 18-month high this month, which has boosted the government’s chance of meeting the target for economic growth set for 2014, by a percentage of 7.5. The Purchasing Managers Index (PMI) preliminary from Markit Economics and HSBC Holdings Plc was at 52.0 and its has topped the 51.0 median estimate. These numbers indicate an above 50 mark. The...
Paracetamol doesn’t speed recovery or reduce low back pain: Study
Jul 24, 2014  
Paracetamol, which has long since been prescribed as a painkiller for severe low back pain, is no better than placebo; findings of a recent study in Australia have shown. The trial that was published on Thursday found that the universally recommended painkiller neither speeds recovery nor reduces the pain. Paracetamol is merely acts as a placebo or dummy pills doing nothing to ease the...
Early Treatment to Cure HIV virus Might not be Effective
Jul 23, 2014  
According to a research study, the virus of AIDS, HIV has the capacity of creating invulnerable strongholds in the host’s body rapidly. This has dashed hopes of early treatment for the condition, which might have been helpful to cure the virus. In one case, a baby was thought to be cured with the new treatment after its birth, however, the virus emerged couple of years later. A...